Literature DB >> 11917050

Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies.

Herbert A Hauer1, Ingeborg M Bajema, E Christiaan Hagen, Laure-Hélène Noël, Franco Ferrario, Rüdiger Waldherr, Hans C van Houwelingen, Philippe Lesavre, Renato A Sinico, Fokko van der Woude, Gill Gaskin, Cornelis A Verburgh, Emile de Heer, Jan A Bruijn.   

Abstract

BACKGROUND: We reported previously that in renal disease in relation to antineutrophil cytoplasm auto-antibodies (ANCA)-associated vasculitis, renal outcome correlates better with the percentage of normal glomeruli than with separate active lesions. This may imply that glomeruli, once affected by necrotizing and crescentic lesions, are irreversibly damaged. We quantified and evaluated the course of renal lesions in the present study.
METHODS: We retrospectively analysed 31 patients with renal disease in relation to ANCA-associated vasculitis, all treated with immunosuppressive drugs. In all patients, a renal biopsy was performed at diagnosis. A follow-up biopsy was performed in all patients on the indication of a suspected renal relapse, after a mean interval of 31 months.
RESULTS: The mean percentage of normal glomeruli in the renal biopsy did not change over time (29% in the initial and 30% in the follow-up biopsy). The mean percentage of glomeruli with crescents, however, significantly decreased from 57 to 30% (P<0.001). The percentage of glomerulosclerosis significantly increased from 12 to 39% (P<0.001). The data were independent of diagnosis, gender, age, time interval between the biopsies, and treatment.
CONCLUSIONS: This is the first study to quantify glomerular changes between two time points in patients with renal vasculitis. Our results suggest that, on average, no new glomeruli are recruited into the active disease process. The sum of the percentage of crescentic and sclerotic glomeruli in the initial biopsies is larger than the percentage of sclerotic glomeruli in the follow-up biopsies. Thus, therapy seems not only to prevent normal glomeruli from being recruited into the active disease process for a certain time, but seems also to allow part of the active lesions to revert into a normal phenotype, although another part of the active lesions will be transformed to a chronic phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917050     DOI: 10.1093/ndt/17.4.587

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

Review 1.  Histopathologic classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: achievements, limitations, and perspectives.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

Review 2.  Vasculitis for the internist: focus on ANCA-associated vasculitis.

Authors:  Benjamin Chaigne; Loïc Guillevin
Journal:  Intern Emerg Med       Date:  2017-06-16       Impact factor: 3.397

Review 3.  Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects.

Authors:  Adam D Morris; Anthony W Rowbottom; Francis L Martin; Alexander Woywodt; Ajay P Dhaygude
Journal:  Kidney360       Date:  2021-01-19

Review 4.  Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan.

Authors:  Kensuke Joh; Eri Muso; Hidekazu Shigematsu; Masato Nose; Michio Nagata; Yoshihiro Arimura; Wako Yumura; Takashi Wada; Kousaku Nitta; Hirofumi Makino; Yoshio Taguma; Hidetoshi Kaneoka; Yuhsuke Suzuki; Masaki Kobayashi; Akio Koyama; Joichi Usui; Hiroshi Hashimoto; Shoichi Ozaki; Yasuhiko Tomino; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2008-04-22       Impact factor: 2.801

Review 5.  Treatment of renal manifestations of ANCA-associated vasculitis.

Authors:  Kresimir Galesic; Danica Ljubanovic; Ivica Horvatic
Journal:  J Nephropathol       Date:  2013-01-01

Review 6.  Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.

Authors:  Marc Hilhorst; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2015-05-08       Impact factor: 10.121

7.  Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine.

Authors:  Clara J Day; Alec J Howie; Peter Nightingale; Shazia Shabir; Dwomoa Adu; Caroline O Savage; Peter Hewins
Journal:  Am J Kidney Dis       Date:  2009-12-31       Impact factor: 8.860

8.  Etiological Spectrum and Clinical Features in 215 Patients of Crescentic Glomerulonephritis: Is it Different in India?

Authors:  Anubha Gupta; Vinita Agrawal; Anupma Kaul; Ritu Verma; Manoj Jain; Narayan Prasad; Rakesh Pandey
Journal:  Indian J Nephrol       Date:  2021-03-08

9.  Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN).

Authors:  Efstathios Alexopoulos; Lazaros Gionanlis; Ekaterini Papayianni; Elizabeth Kokolina; Maria Leontsini; Dimitrios Memmos
Journal:  BMC Nephrol       Date:  2006-11-01       Impact factor: 2.388

10.  Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome.

Authors:  Carla L Ellis; Rebecca L Manno; John P Havill; Lorraine C Racusen; Duvuru Geetha
Journal:  BMC Nephrol       Date:  2013-10-04       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.